Patritumab Deruxtecan: Paving the Way for EGFR-TKI-Resistant NSCLC

Abstract

HER3 is ubiquitously expressed in EGFR -mutant non-small cell lung cancer (NSCLC) irrespective of resistant mechanisms to EGFR tyrosine kinase inhibitors, thus garnering attention as a valuable therapeutic target. In this issue of Cancer Discovery , Janne and colleagues highlight early clinical data supporting patritumab deruxtecan as a potentially appreciable agent for previously treated EGFR-mutant NSCLC.